Buy & Sell Procter & Gamble Co (PG) – Procter & Gamble Co Price Today
Aura AI Summary
Key Stats
- $335.11BMarket Cap
- Consumer StaplesSector
- -15.48%3M Drawdown
- $360.59BEnterprise Value
- 2.96%Dividend Yield
- 32% Buy | 68% SellTrading Activity
- 127 daysTypical Hold Time
Procter & Gamble Co (PG) is currently valued at a market capitalization of $335.11B, with an enterprise value of $360.59B. Over the past 52 weeks, Procter & Gamble Co has traded between a low of $138.1 and a high of $169.89, highlighting its annual price range. Over the past three months, Procter & Gamble Co has recorded a drawdown of -15.48%, reflecting recent price volatility. Procter & Gamble Co offers a dividend yield of 2.96%, with the most recent dividend of $1.09 paid on 24 Apr 26. On average, investors hold Procter & Gamble Co for approximately 127 days, indicating typical investor behavior on the platform.
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Most Recent News
Cerebras IPO signals market caution amid AI deployment delays and high valuations.
Cerebras Systems is set to go public with an IPO expected to value the company at over $50 billion, despite underlying operating losses. This IPO highlights market concerns as AI deployment at scale remains slow, with only 19% of companies reporting ...
Chinese solar firms cut U.S. stakes amid Trump-era subsidy cuts and IPO withdrawals signal tighter U.S.-China market controls.
Chinese solar manufacturers are reducing their ownership in U.S. operations due to new Trump administration rules limiting subsidies for China-linked solar panels made in the U.S. Companies like JinkoSolar are selling majority stakes in their U.S. su...
Eli Lilly's new drugs Foundayo and lower-dose Zepbound help sustain weight loss in obesity patients.
Eli Lilly released positive results from two late-stage obesity studies showing that patients maintained significant weight loss after switching to either Foundayo or a lower dose of Zepbound. The SURMOUNT-MAINTAIN trial showed continued weight loss ...
